Key facts
- Kiin Bio’s last known valuation is $9.8M (Jun 2025).
- It has raised $2.2M; the latest was Accelerator/Incubator in Nov 2025.
- Notable investors include b2venture, BioIndustry Association, Heartfelt Ventures, rule30.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Kiin Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Kiin Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kiin Bio
Developer of an end-to-end AI scientist designed to execute complex scientific tasks. The company's technology specializes in designing, conducting, and troubleshooting tasks related to drug discovery and accelerating the development of new medications, enabling clients to get help with research planning and reasoning across biology and chemistry.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 10
- Website
- kiin.bio/
- Ownership
- Privately Held (backing)
Kiin Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kiin Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kiin Bio in its N-PORT filings yet. We sweep new filings monthly.